Trial Profile
Immunosuppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 May 2012
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Calcineurin inhibitors
- Indications Transplant rejection
- Focus Therapeutic Use
- Acronyms Everopolm
- 09 Aug 2011 New trial record